NCM · Biotechnology

Apollomics Inc. (APLM) Stock

$21.72 -0.28% NCM: APLM Healthcare

Valuation

MetricValue
Price$21.72
Market Cap$47.70M
P/E Ratio-2.84
P/B Ratio-2.84
P/S Ratio5.55
EPS (TTM)$-7.57
52-Week High$42.12
52-Week Low$10.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE288.40%
ROA-162.93%
ROCE-900.00%
Gross Margin-100.00%
Operating Margin-100.00%
Net Margin-128.69%
Debt/Equity-0.20
Current Ratio1.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$0$9.0M
Operating Profit$-51.0M$-45.0M$-54.0M$-42.0M$-9.0M
Net Profit$-95.0M$-241.0M$-173.0M$-54.0M$-11.0M
EPS$-23.45$-61.60$-231.99$-52.80$-7.57
Op Margin-2542850.0%-13957.0%-6578.9%-21280.8%-111.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$123.0M$76.0M$55.0M$13.0M$7.0M
Total Liabilities$336.0M$525.0M$14.0M$8.0M$10.0M
Cash$47.0M$33.0M$32.0M$10.0M$3.0M
Borrowings$325.0M$1.0M$5.0M$1.0M$1.0M

Latest News

Apollomics Regains Full Compliance with Nasdaq Listing Requirements GlobeNewswire · Jul 13, 2026 Apollomics Receives Nasdaq Deficiency Notice Over Market Value Requirement MT Newswires · Jun 24, 2026 Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia GlobeNewswire · Jun 24, 2026 Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress GlobeNewswire · Apr 27, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-43.0M$-43.0M$-43.0M$-29.0M$-10.0M
Investing Cash Flow$-46.0M$29.0M$21.0M$6.0M$0
Financing Cash Flow$-1.0M$0$-3.0M$0$0
Net Cash Flow$-84.0M$-14.0M$-1.0M$-22.0M$-6.0M
Free Cash Flow$-51.0M$-43.0M$-43.0M$-29.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-4.71
FCF Yield-21.96%
Quick Ratio0.96
Interest Coverage-145.74
Return 1Y219.83%
Return 3Y-96.57%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%
BLRXBioLineRx Ltd. $2.85 -2.45% -1.36 $12.39M 0.00%
GOVXGeoVax Labs, Inc. $0.29 +1.01% -0.02 $2.13M 0.00%

About Apollomics Inc.

Apollomics Inc. is led by CEO Hung-Wen Chen, employs 13 people, headquartered in US, publicly traded since 2021.

Apollomics Inc. (APLM) stock trades at $21.72 with a market capitalization of $47.70M. The stock is valued at a price-to-earnings (P/E) ratio of -2.84, price-to-book of -2.84, price-to-sales of 5.55. Over the past 52 weeks the stock has ranged between $10.01 and $42.12, and currently trades 48.4% below its 52-week high.

On profitability, Apollomics Inc. generates a return on equity (ROE) of 288.40% — well above the market average, a sign of a high-quality business, return on capital employed of -900.00%, an operating margin of -100.00%, a net profit margin of -128.69%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1175.87 +0.54% JNJ Johnson & Johnson $260.28 +1.48% ABBV AbbVie Inc. $276.32 +1.43% MRK Merck & Company, Inc. Common Stock (new) $146.30 +2.75% UNH UnitedHealth Group Incorporated Common Stock (DE) $381.94 +2.96% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $658.24 +0.96% AMGN Amgen Inc. $415.91 +2.08% GILD Gilead Sciences, Inc. $150.59 +2.37% ABT Abbott Laboratories $99.58 +1.10% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides